List of Coreg Cr drug patents

Coreg Cr is owned by Woodward.

Coreg Cr contains Carvedilol Phosphate.

Coreg Cr has a total of 4 drug patents out of which 0 drug patents have expired.

Coreg Cr was authorised for market use on 20 October, 2006.

Coreg Cr is available in capsule, extended release;oral dosage forms.

Coreg Cr can be used as treatment of hypertension; treatment of congestive heart failure.

The generics of Coreg Cr are possible to be released after 11 March, 2026.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7268156 WOODWARD Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Jun, 2023

(4 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7268156

(Pediatric)

WOODWARD Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
Dec, 2023

(10 months from now)

US8101209 WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Sep, 2025

(2 years from now)

US8101209

(Pediatric)

WOODWARD Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
Mar, 2026

(3 years from now)

Drugs and Companies using CARVEDILOL PHOSPHATE ingredient

Market Authorisation Date: 20 October, 2006

Treatment: Treatment of hypertension; Treatment of congestive heart failure

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of COREG CR before it's patent expiration?
More Information on Dosage

COREG CR family patents

10

United States

8

China

5

Korea, Republic of

5

Japan

4

European Union

3

Canada

2

Brazil

2

South Africa

2

Australia

2

France

2

Israel

2

Mexico

1

Hong Kong

1

Norway

1

Spain

1

New Zealand

1

EA

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic